The domestic entry of the biosimilar of Lantus will create a powerful diabetic lineup for BI-Lilly
Boehringer Ingelheim and Lilly (hereinafter referring to BI-Lilly)are about to dominate the diabetic treatment market.
They are preparing entry of the biosimilar product of the Sanofi’s basal insulin release ‘Lantus (insulin glargine)’. The current manufacturer of the product, Lilly, is getting ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
